Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
暂无分享,去创建一个
P. Kaesberg | J. Tuscano | J. Welborn | Tamer Othman | B. Jonas | Matthew E. Tenold | Benjamin N. Moskoff | R. Hoeg | A. Rosenberg | M. Abedi | Gwendolyn Ho | Theodore Wun | L. Potter | Samantha C. Fisch | M. Krackeler | Tali Azenkot | Naseem S. Esteghamat